Mesa Biotech designs, develops, manufactures and commercializes next-generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care. Mesa’s proprietary OSCAR technology is key to the patented and patent-pending diagnostic solutions. The technology offers the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays while providing the superior sensitivity and specificity of laboratory-based molecular testing.
Mesa Biotech has developed a qualitative, visually read test utilizing polymerase chain reaction (PCR) technology to detect SARS-CoV-2, the virus responsible for COVID-19. Using throat and nasal swabs, results are available in 30 minutes, based on the principles of Mesa’s commercially available Accula Influenza and RSV test.